📊 RDHL Key Takeaways
Is RedHill Biopharma Ltd. (RDHL) a Good Investment?
No financial data available in SEC EDGAR filings to perform fundamental analysis. All key metrics—revenue, profitability, assets, liabilities, and cash flow—are unavailable. Investment assessment impossible without audited financial statements.
No fresh SEC financials are available, preventing a clear read on profitability, liquidity, and cash runway. Until updated filings show sustainable revenue traction, improving margins, and reduced cash burn, the fundamental risk/reward remains unclear.
Why Buy RedHill Biopharma Ltd. Stock? RDHL Key Strengths
- No strengths identified
- Potential operating leverage if commercialization scales
- High gross margin potential for successful therapies
- Option value from partnerships or out-licensing to offset burn
RDHL Stock Risks: RedHill Biopharma Ltd. Investment Risks
- Complete absence of financial data in SEC filings
- Unable to assess profitability or revenue trends
- Unable to evaluate balance sheet health and solvency
- Unable to assess cash flow generation and liquidity position
- Data quality failure prevents any meaningful analysis
- Lack of current SEC financials signals visibility and reporting risk
- Possible ongoing losses and cash burn requiring dilution or costly financing
- Regulatory/clinical and commercial execution risks with likely revenue concentration
Key Metrics to Watch
- Latest 10-K filing with complete financial statements
- Revenue and gross profit
- Operating cash flow and free cash flow
- Cash reserves and debt levels
- Operating cash flow (burn) trend
- Cash & equivalents and months of runway
RedHill Biopharma Ltd. (RDHL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RDHL Profit Margin, ROE & Profitability Analysis
RDHL vs Healthcare Sector: How RedHill Biopharma Ltd. Compares
How RedHill Biopharma Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RedHill Biopharma Ltd. Stock Overvalued? RDHL Valuation Analysis 2026
Based on fundamental analysis, RedHill Biopharma Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RedHill Biopharma Ltd. Balance Sheet: RDHL Debt, Cash & Liquidity
RDHL Revenue Growth, EPS Growth & YoY Performance
RDHL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for RedHill Biopharma Ltd. (CIK: 0001553846)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RDHL
What is the AI rating for RDHL?
RedHill Biopharma Ltd. (RDHL) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 16% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RDHL's key strengths?
Claude: . ChatGPT: Potential operating leverage if commercialization scales. High gross margin potential for successful therapies.
What are the risks of investing in RDHL?
Claude: Complete absence of financial data in SEC filings. Unable to assess profitability or revenue trends. ChatGPT: Lack of current SEC financials signals visibility and reporting risk. Possible ongoing losses and cash burn requiring dilution or costly financing.
What is RDHL's revenue and growth?
RedHill Biopharma Ltd. reported revenue of N/A.
Does RDHL pay dividends?
RedHill Biopharma Ltd. does not currently pay dividends.
Where can I find RDHL SEC filings?
Official SEC filings for RedHill Biopharma Ltd. (CIK: 0001553846) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RDHL's EPS?
RedHill Biopharma Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RDHL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, RedHill Biopharma Ltd. has a HOLD rating with 16% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RDHL stock overvalued or undervalued?
Valuation metrics for RDHL: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RDHL stock in 2026?
Our dual AI analysis gives RedHill Biopharma Ltd. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RDHL's free cash flow?
RedHill Biopharma Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does RDHL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).